Exact Sciences
EXAS · NASDAQ
Bulios Fair Price
$97.58
7.0% downside
Current Price
$104.91
According to Bulios Fair Price, EXAS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Exact Sciences Corporation (EXAS) is an American company that specializes in the development and commercial distribution of diagnostic tests for cancer prevention and detection. Their main product is Cologuard, a non-invasive stool test used for detecting colorectal cancer and advanced adenomas. This test allows patients to undergo cancer screening at home, providing significant advantages compared to traditional screening methods such as colonoscopies. In addition to this, Exact Sciences invests in research and development of new diagnostic tests for various types of cancer and other diseases. Exact Sciences Corporation (EXAS) shares may be attractive to investors seeking investments in companies operating in the cancer diagnostics field with an emphasis on innovation and improving healthcare.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Kevin T. Conroy
Employees
6,900
Headquarters
Madison